We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+8.01%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$20.1B
AUM Growth
+$3.5B
Cap. Flow
+$2.5B
Cap. Flow %
12.41%
Top 10 Hldgs %
33.13%
Holding
257
New
120
Increased
40
Reduced
39
Closed
20

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$546M
2
WTW icon
Willis Towers Watson
WTW
+$471M
3
MA icon
Mastercard
MA
+$344M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$240M
5
BBL
BHP Group Plc American Depositary Shares (Each representing two Ordinary Shares)
BBL
+$238M

Top Sells

Rank Stock Value
1
TIF
Tiffany & Co.
TIF
+$301M
2
NYT icon
New York Times
NYT
+$209M
3
V icon
Visa
V
+$194M
4
ELV icon
Elevance Health
ELV
+$145M
5
ABBV icon
AbbVie
ABBV
+$123M

Sector Composition

Rank Sector Weight
1 Healthcare 35.71%
2 Technology 14.95%
3 Financials 13.65%
4 Communication Services 11.15%
5 Industrials 7.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACHL
101
DELISTED
Achilles Therapeutics
ACHL
$16.6M 0.08%
+1,000,000
New +$16.6M
ZEAL
102
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
$16.3M 0.08%
510,000
– –
RCEL icon
103
Avita Medical
RCEL
$311M
$15.9M 0.08%
+800,000
New +$18.6M
BEKE icon
104
KE Holdings
BEKE
$19.6B
$15.6M 0.08%
273,000
-70,000
-20% -$4.4M
RCKT icon
105
Rocket Pharmaceuticals
RCKT
$385M
$15.5M 0.08%
350,000
+150,000
+75% +$8.24M
ASZ.U
106
DELISTED
Austerlitz Acquisition Corporation II Units, each consisting of one Class A ordinary share and one-fourth of one redeemable warrant
ASZ.U
$15M 0.07%
+1,500,000
New +$15.2M
KAHC.U
107
DELISTED
KKR Acquisition Holdings I Corp. Units, each consisting of one share of Class A Common Stock and one-fourth of one redeemable warrant
KAHC.U
$15M 0.07%
+1,500,000
New +$15M
ADVM
108
DELISTED
Adverum Biotechnologies
ADVM
$14.8M 0.07%
150,000
– –
STAY
109
DELISTED
Extended Stay America, Inc. Paired Share Unit
STAY
$14.1M 0.07%
+715,499
New +$11.7M
DISAU
110
DELISTED
Disruptive Acquisition Corporation I Unit
DISAU
$13.8M 0.07%
+1,400,000
New +$13.8M
DCPH
111
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$13.5M 0.07%
300,000
– –
LBPH
112
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$13.3M 0.07%
+810,500
New +$13.2M
CMRX
113
DELISTED
Chimerix, Inc.
CMRX
$12.5M 0.06%
+1,300,000
New +$11.9M
FRXB.U
114
DELISTED
Forest Road Acquisition Corp. II Units, each consisting of one share of Class A common stock, and one-fifth of one redeemable warrant
FRXB.U
$12.4M 0.06%
+1,250,000
New +$12.6M
GRFS
115
Grifois
GRFS
$5.44B
$12.1M 0.06%
702,110
-412,890
-37% -$7.14M
INBX
116
DELISTED
Inhibrx, Inc. Common Stock
INBX
$12M 0.06%
600,000
+90,000
+18% +$2.63M
AGGRU
117
DELISTED
Agile Growth Corp Units
AGGRU
$11.9M 0.06%
+1,200,000
New +$11.9M
DRIO icon
118
DarioHealth
DRIO
$73.4M
$11.6M 0.06%
+30,000
New +$13.5M
ARWR icon
119
Arrowhead Research
ARWR
$12.3B
$11.4M 0.06%
172,454
+104,854
+155% +$8.14M
CRIS icon
120
Curis
CRIS
$3.83M
$11.3M 0.06%
2,500
+687
+38% +$2.87M
KURA icon
121
Kura Oncology
KURA
$1.06B
$11.3M 0.06%
400,000
+275,000
+220% +$8.7M
NGM
122
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$10.9M 0.05%
+375,000
New +$10.5M
GRND icon
123
Grindr
GRND
$2.7B
$10.8M 0.05%
+1,080,000
New +$11.4M
DMTK
124
DELISTED
DermTech, Inc. Common Stock
DMTK
$10.2M 0.05%
200,000
-661,090
-77% -$34.6M
QURE icon
125
uniQure
QURE
$3.36B
$10.1M 0.05%
300,000
– –
3 4
5
6 7

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q1 2021 Portfolio in Review

As of Q1 2021, Thomas Steyer held 257 positions worth $20.1B, up 21% from $16.6B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Thomas Steyer deployed $2.5B of net new capital in Q1 2021, opening 120 new positions and adding to 40 existing holdings. Its largest new stake was Mastercard: 985,920 shares worth $351M.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, down from 39% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was New York Times, an estimated $209M trimmed.

  • Thomas Steyer's largest Q1 2021 buy was Mastercard: 985,920 shares worth $351M.
  • Thomas Steyer added most to Alexion Pharmaceuticals in Q1 2021, an estimated $546M increase.
  • Thomas Steyer's biggest Q1 2021 reduction was New York Times, cutting an estimated $209M.
  • Thomas Steyer fully exited Tiffany & Co. in Q1 2021, selling an estimated $301M.
  • Thomas Steyer's ten largest holdings make up 33% of its $20.1B portfolio in Q1 2021.
  • Thomas Steyer opened 120 new positions and closed 20 in Q1 2021.
  • Thomas Steyer's portfolio value rose 21% quarter-over-quarter to $20.1B.

Based on Farallon Capital Management's 13F filing for Q1 2021, filed 17 May 2021.